Merck mulls options for animal-health and consumer ops

Merck (MRK +3.1%) is considering its options for its animal health and consumer-care operations and plans to carry out any moves this year.

The pharmaceutical company said it "could reach different decisions" about the businesses.

Merck's comments follow reports last week that the company is in talks with Novartis about the Swiss pharmaceuticals company swapping its animal-health and human vaccines businesses for the U.S. drug maker's over-the-counter health-products unit. (PR)

As part of a plan announced in October, Merck expects to cut annual operating costs by $2.5B by the end of 2015 vs 2012, with $1B to be realized by the end of this year.

Meanwhile, Merck has started the process of applying for approval of its MK-3475 immunotherapy for patients with advanced melanoma who have stopped responding to Bristol-Myer Squibb's (BMY) Yervoy. Merck expects to complete the initial filing this year. (PR)

From other sites
Comments (1)
  • biochemist
    , contributor
    Comments (797) | Send Message
    Hey SA Editors,


    You may not understand that the MK-3475 news is the big news here, not the vorapaxar news. I can't believe that there wasn't a separate alert for the MK-3475 news and that the news that was published was appended to the vorapaxar piece. What news do you think drove the stock price rise today?
    13 Jan 2014, 08:12 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs